Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE56.3000
- TODAY'S CHANGE (%)1.8100 (3.3217%)
- Bid / Lots23.0500/ 1
- Ask / Lots59.9600/ 1
- Open / Previous Close54.4900 / 54.4900
- Day Range
- 52 Week Range
- Volume327,702
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 3738 | 54.075 |
| 09:35 ET | 100 | 52.37 |
| 09:39 ET | 700 | 53.735 |
| 09:42 ET | 7406 | 54.145 |
| 09:44 ET | 1168 | 53.93 |
| 09:46 ET | 100 | 54.22 |
| 09:48 ET | 650 | 54.49 |
| 09:50 ET | 400 | 54.86 |
| 09:51 ET | 200 | 55.39 |
| 09:53 ET | 100 | 55.32 |
| 09:57 ET | 600 | 53.96 |
| 10:00 ET | 700 | 54.535 |
| 10:02 ET | 100 | 55.06 |
| 10:04 ET | 100 | 54.88 |
| 10:06 ET | 2961 | 54.98 |
| 10:08 ET | 100 | 54.92 |
| 10:09 ET | 900 | 54.99 |
| 10:11 ET | 200 | 54.95 |
| 10:13 ET | 400 | 54.9 |
| 10:15 ET | 400 | 54.028 |
| 10:18 ET | 1422 | 53.59 |
| 10:20 ET | 532 | 53.79 |
| 10:24 ET | 200 | 53.99 |
| 10:26 ET | 700 | 53.8 |
| 10:27 ET | 977 | 54.25 |
| 10:29 ET | 803 | 53.995 |
| 10:36 ET | 1030 | 54.18 |
| 10:40 ET | 600 | 54 |
| 10:42 ET | 838 | 54 |
| 10:44 ET | 800 | 54.305 |
| 10:45 ET | 100 | 54.305 |
| 10:49 ET | 290 | 54.305 |
| 10:58 ET | 4722 | 54.038 |
| 11:00 ET | 835 | 54.35 |
| 11:05 ET | 600 | 54.73 |
| 11:09 ET | 200 | 54.735 |
| 11:12 ET | 551 | 54.58 |
| 11:18 ET | 1439 | 54.89 |
| 11:21 ET | 100 | 55.015 |
| 11:27 ET | 200 | 55.005 |
| 11:36 ET | 200 | 54.8 |
| 11:39 ET | 400 | 54.66 |
| 11:41 ET | 100 | 54.71 |
| 11:45 ET | 300 | 54.698 |
| 11:52 ET | 200 | 54.69 |
| 11:54 ET | 400 | 54.52 |
| 11:56 ET | 100 | 54.745 |
| 12:03 ET | 200 | 54.68 |
| 12:06 ET | 1005 | 54.98 |
| 12:10 ET | 100 | 54.765 |
| 12:14 ET | 200 | 55 |
| 12:17 ET | 100 | 55.29 |
| 12:19 ET | 100 | 55.115 |
| 12:24 ET | 500 | 55.33 |
| 12:28 ET | 100 | 55.5 |
| 12:30 ET | 100 | 55.66 |
| 12:32 ET | 100 | 55.52 |
| 12:33 ET | 100 | 55.52 |
| 12:35 ET | 200 | 55.64 |
| 12:37 ET | 300 | 55.67 |
| 12:42 ET | 300 | 55.9 |
| 12:44 ET | 100 | 55.99 |
| 12:48 ET | 100 | 56.06 |
| 12:50 ET | 100 | 56.02 |
| 12:51 ET | 500 | 55.945 |
| 12:53 ET | 3693 | 55.73 |
| 12:55 ET | 100 | 55.67 |
| 12:57 ET | 100 | 55.55 |
| 01:00 ET | 100 | 55.5 |
| 01:04 ET | 400 | 55.605 |
| 01:06 ET | 1214 | 55.26 |
| 01:08 ET | 200 | 55.69 |
| 01:09 ET | 300 | 55.55 |
| 01:11 ET | 4605 | 55.98 |
| 01:13 ET | 600 | 56.305 |
| 01:15 ET | 320 | 56.005 |
| 01:22 ET | 100 | 56.35 |
| 01:24 ET | 100 | 55.99 |
| 01:26 ET | 100 | 56.31 |
| 01:27 ET | 220 | 55.98 |
| 01:33 ET | 100 | 56.28 |
| 01:36 ET | 224 | 55.985 |
| 01:38 ET | 200 | 56.075 |
| 01:40 ET | 100 | 56.09 |
| 01:42 ET | 100 | 56.11 |
| 01:44 ET | 717 | 56.34 |
| 01:45 ET | 100 | 56.39 |
| 01:47 ET | 300 | 56.39 |
| 01:58 ET | 100 | 56.3 |
| 02:00 ET | 200 | 56.17 |
| 02:09 ET | 731 | 56.29 |
| 02:12 ET | 200 | 56.27 |
| 02:16 ET | 800 | 56.36 |
| 02:18 ET | 184 | 56.31 |
| 02:20 ET | 200 | 56.4 |
| 02:21 ET | 500 | 56.59 |
| 02:25 ET | 100 | 56.62 |
| 02:36 ET | 300 | 56.29 |
| 02:38 ET | 20812 | 56.29 |
| 02:39 ET | 4498 | 55.72 |
| 02:43 ET | 1718 | 55.715 |
| 02:45 ET | 500 | 55.945 |
| 02:48 ET | 200 | 56 |
| 02:52 ET | 600 | 55.965 |
| 02:56 ET | 200 | 56.13 |
| 02:57 ET | 13405 | 56.32 |
| 02:59 ET | 200 | 56.44 |
| 03:01 ET | 3295 | 56.53 |
| 03:03 ET | 500 | 56.73 |
| 03:06 ET | 500 | 56.75 |
| 03:08 ET | 4324 | 56.86 |
| 03:10 ET | 100 | 56.875 |
| 03:12 ET | 400 | 56.875 |
| 03:14 ET | 300 | 56.875 |
| 03:15 ET | 4690 | 56.74 |
| 03:17 ET | 300 | 56.61 |
| 03:19 ET | 2400 | 56.765 |
| 03:21 ET | 1679 | 56.95 |
| 03:24 ET | 300 | 56.85 |
| 03:26 ET | 300 | 56.91 |
| 03:28 ET | 300 | 56.89 |
| 03:30 ET | 7380 | 56.67 |
| 03:32 ET | 300 | 56.596 |
| 03:33 ET | 500 | 56.48 |
| 03:35 ET | 500 | 56.465 |
| 03:37 ET | 1019 | 56.58 |
| 03:39 ET | 700 | 56.47 |
| 03:42 ET | 400 | 56.375 |
| 03:44 ET | 600 | 56.245 |
| 03:46 ET | 4452 | 56.09 |
| 03:48 ET | 800 | 56.11 |
| 03:50 ET | 5773 | 56.25 |
| 03:51 ET | 2200 | 56.26 |
| 03:53 ET | 1100 | 56.26 |
| 03:55 ET | 4298 | 56 |
| 03:57 ET | 10868 | 55.885 |
| 04:00 ET | 59712 | 56.3 |
Yesterday
Oct 25, 2024
DJ Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush, from 11:19AM ET on Friday Oct 25, 2024 by Dow Jones
11:19AM ET on Friday Oct 25, 2024 by Dow Jones
Oct 24, 2024
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 16, 2024
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.2B | -25.1x | --- |
Edgewise Therapeutics Inc | 3.2B | -22.5x | --- |
Xenon Pharmaceuticals Inc | 3.2B | -15.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
MoonLake Immunotherapeutics | 3.0B | -51.3x | --- |
Iovance Biotherapeutics Inc | 3.4B | -6.8x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -25.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
